The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, ...
GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted ...
CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...
Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a ...
Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary cell-free expression technology on a commercial scale to manufacture ...
PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an ...
US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma: London, UK Wednesday, January 8, 2025, 10:00 ...
We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...
CytomX Therapeutics (CTMX) stock slips as company announces staff reductions as part of a portfolio reorganization. Read more ...
Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen's RenLite® meets Acepodia's AD2C for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback